In a preclinical study, it was demonstrated in a JAK2-V617F mouse model that IFNα was able to eliminate PV-like disease in a selective manner by targeting JAK2-VF617F hematopoietic stem cells over JAK2-WT cells [171,172]. The gene discussed is JAK2; the disease is acquired polycythemia vera.